What changed for Gastro-oesophageal Reflux Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Gastro-oesophageal Reflux Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 101 to 105 (+4)
- Late-stage (Phase 3) trials 2 to 3 (+1)
- Trials on record 1,124 to 1,137 (+13)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Gastro-oesophageal Reflux Disease in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 43 trials tracked for Gastro-oesophageal Reflux Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03820947 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03820947) looked at a device called the VenaSeal™ System, which uses a type of medical glue to close off problem veins in the legs. It was compared against two other approaches: endothermal ablation (ETA, which uses heat to close veins) and surgical stripping (a procedure to physically remove the vein). The trial ran across three groups: 136 people received VenaSeal™ and 139 received ETA in one comparison; 53 received VenaSeal™ and 53 received surgical stripping in another; and a separate group of 125 people with venous le...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06391177 · results posted 25 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 breastfeeding participants in total — 5 in a group taking vonoprazan 20 mg once a day, and 10 in a group taking vonoprazan 20 mg twice a day. All 15 participants completed the study. The trial was measuring how much of the medicine vonoprazan passes into breast milk, by tracking its concentration in breast milk at various points over a 24-hour period. The reported data shows several concentration measurements from breast milk samples. For the once-daily group, the total amount of drug detected in breast milk over...
-
NCT01869491 · results posted 13 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,107 people in total — 552 in the sodium alginate chewable tablet group and 555 in the placebo (dummy tablet) group. The trial ran for 7 days and was measuring changes in symptoms of heartburn and acid reflux (also called gastro-oesophageal reflux disease, or GERD). Participants filled in a standardised questionnaire called the Reflux Disease Questionnaire (RDQ), which uses a scoring system to capture how often and how badly they experienced heartburn, acid regurgitation, and indigestion-like symptoms. Lower scores o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03366012 · results posted 8 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03366012) involved 51 participants, all of whom completed the study with no drop-outs. The trial was looking at a device called the Cytosponge — a capsule attached to a string that, when swallowed, expands into a small sponge and collects cells from the food pipe (oesophagus) as it is pulled back out. The study was measuring how many eligible people were willing to try the test, how comfortable the test felt, and whether it could identify signs of a condition called Barrett's oesophagus (where the lining of the food pipe c...
-
NCT05366738 · results posted 29 March 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 27 adults in total, divided into three groups of nine people, each receiving the three study treatments in a different order. The trial was measuring how the body absorbs and processes vonoprazan — a medicine used for stomach acid-related conditions — depending on how it was taken: as a sprinkle capsule mixed into pudding, as a sprinkle capsule mixed into applesauce, or as a standard tablet. The key things being measured were how much of the medicine got into the bloodstream and how quickly it reached its highest leve...
-
NCT04301986 · results posted 8 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04301986) enrolled 24 participants, all of whom completed the study. The trial was looking at how people felt about three different procedures used to examine the oesophagus (the tube connecting your throat to your stomach): swallowing a small capsule on a string called a Cytosponge, a thin flexible camera passed through the nose called Transnasal Endoscopy (TNE), and a standard camera procedure done under sedation called an Esophagogastroduodenoscopy (EGD). The study measured things like emotional distress after the proce...
-
NCT03193216 · results posted 8 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03193216) involved two groups of people with a condition called Barrett's Oesophagus — a change in the lining of the food pipe that can sometimes be associated with a risk of further changes over time. One group of 24 people received a combination of a standard acid-reducing medicine (called a PPI) together with a liquid alginate solution (a seaweed-derived substance sometimes used to coat the stomach). This group was compared against a historical control group of 21 people who had previously been treated with the PPI medi...
-
NCT02699060 · results posted 18 February 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 68 participants, all of whom had a condition called GERD (gastro-oesophageal reflux disease, where stomach contents flow back up into the oesophagus). All 68 participants completed the study with none dropping out. The trial was measuring the number of reflux episodes — moments when stomach contents travel back up — in three different sub-groups of GERD patients: those with Non-Erosive Reflux Disease (NERD, where there is no visible damage to the oesophagus), those with Erosive Oesophagitis (EE, where there is visible...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03561883 · results posted 18 August 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 609 people in total — 305 in a group receiving a placebo (a dummy treatment) twice daily alongside standard acid-reducing medicines called PPIs (proton pump inhibitors), and 304 in a group receiving 1,500 mg of a medicine called IW-3718 twice daily alongside the same PPIs. The trial was measuring changes in heartburn symptoms over 8 weeks, using a scoring system where participants rated their heartburn severity each day on a scale from 0 (no symptoms) to 5 (severe). Around 520 of the 609 participants completed the stu...
-
NCT03561090 · results posted 18 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03561090) enrolled 495 adults who had ongoing heartburn symptoms despite already taking a standard acid-suppressing medicine called a proton pump inhibitor (PPI). Participants were randomly split into two groups: one group (246 people) received a dummy tablet (placebo) twice a day alongside their PPI, and the other group (247 people) received a medicine called IW-3718 (1500 mg) twice a day alongside their PPI. The trial ran for 8 weeks and was primarily measuring changes in heartburn severity, scored using a diary-based ra...
-
NCT03020550 · results posted 15 January 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people in total — 8 in the "Standard Visit" group and 16 in the "Expanded Visit" group. All 24 participants completed the study. The trial was measuring body signals during a doctor's visit — specifically, skin electrical activity (called galvanic skin response, or GSR) and heart rate patterns (called heart rate variability, or HRV) — to see whether changes in those signals during the visit were linked to the severity of heartburn and reflux (GERD) symptoms reported by patients two weeks later. It also looked at wh...
-
NCT03014453 · results posted 26 March 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 187 extremely premature babies who had been diagnosed with bronchopulmonary dysplasia (BPD) — a lung condition that can develop in babies born very early. Of the 187 who started the study, 116 completed it, while 71 did not finish. The trial followed these infants over their first year of life (adjusted for how early they were born) and tracked a range of health complications using questionnaires completed at 3, 6, 9, and 12 months. The reported data shows the number of infants who experienced various complications d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02552966 · results posted 26 February 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 participants in a single group, referred to as "UESAD." Of those, 15 people completed the study and 5 did not finish. The trial was measuring levels of a substance called pepsin in saliva — pepsin is a digestive enzyme that is normally found in the stomach — as well as several symptom scores related to reflux and respiratory (breathing and throat) symptoms. The reported data shows that the average pepsin concentration in saliva across participants was 158.4 ng/mL (nanograms per millilitre, a measure of how much of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02637557 · results posted 15 October 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02637557) enrolled 282 adults across four groups to test a drug called IW-3718 for heartburn. Participants were randomly assigned to take either a dummy pill (placebo) or one of three doses of IW-3718 — 500 mg, 1,000 mg, or 1,500 mg — twice a day for 8 weeks. The main thing being measured was how much participants' weekly heartburn severity scores changed over the course of the trial. Heartburn severity was tracked daily using a 0–5 scale (where 0 meant no heartburn and 5 meant severe), and a lower score over time indicate...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02135107 · results posted 19 November 2018
According to the results reported on ClinicalTrials.gov, this trial looked at a stomach acid medication called rabeprazole in people with a condition involving inflammation of the oesophagus (the tube connecting your mouth to your stomach). The trial had two main stages. In the first stage, 437 people received rabeprazole 10 mg twice daily and 80 received 20 mg twice daily. Those who responded then moved into a second, maintenance stage, where 178 people were switched to a lower dose of 10 mg once daily and 181 continued on 10 mg twice daily. The trial was mainly measuring how many people had...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02200055 · results posted 28 August 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 86 participants, all of whom completed the study with no drop-outs. The trial was measuring something called **bioimpedance** — a technique that passes a tiny electrical signal through the body to estimate how fluid is distributed across different body compartments. Measurements were taken at three points: before a surgical procedure, six hours after the procedure, and across the broader postoperative (after surgery) period. The trial also tracked how fluid was split between the spaces inside and outside the body's ce...
-
NCT00388453 · results posted 27 June 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 47 people across three groups: 20 healthy volunteers with no history of reflux or acid-suppressing medication use, 17 people with a history of gastro-oesophageal reflux disease (GORD — a condition where stomach acid regularly flows back into the food pipe), and 10 people with laryngopharyngeal reflux (LPR — a condition where stomach acid travels all the way up to the throat). All 47 participants completed the study with no dropouts reported. The trial measured acid levels at two locations — the lower food pipe and the...
-
NCT00444145 · results posted 29 March 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT00444145) enrolled 38 participants, all of whom received a medication called Prevacid (lansoprazole). The trial was looking at a specific physical change in the cells lining the oesophagus (the tube connecting the mouth to the stomach) called "dilation of intracellular spaces." In simple terms, this refers to whether the tiny gaps between cells in the oesophagus lining had become enlarged — something researchers consider a possible early structural sign of gastro-oesophageal reflux (where stomach acid travels back up into...
-
NCT00911534 · results posted 2 February 2016
According to the results reported on ClinicalTrials.gov, this trial enrolled 300 people in total — 147 in the placebo group (a dummy treatment with no active ingredient) and 153 in the group taking a 50 mg extended-release form of rabeprazole (RAB ER 50mg), a medicine used for acid-related stomach and oesophagus conditions. The trial was measuring symptoms of gastro-oesophageal reflux disease (GORD — commonly known as acid reflux), particularly heartburn, over a four-week period. Participants kept a daily diary recording their symptoms. By the end of the study, 132 people in the placebo group...
-
NCT00839306 · results posted 16 November 2015
According to the results reported on ClinicalTrials.gov, this trial compared two treatments for erosive gastro-oesophageal reflux disease (eGERD) — a condition where stomach acid causes sores in the oesophagus (the tube connecting your mouth to your stomach). One group received a medicine called ranitidine (RAN) at 150mg twice a day, and the other received rabeprazole extended-release (RAB ER) at 50mg once a day. A total of 60 people started in the ranitidine group and 177 in the rabeprazole group. By the end of the study, 35 people in the ranitidine group and 134 in the rabeprazole group had...
-
NCT00734747 · results posted 14 August 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 72 participants who all received a procedure using a device called the Medigus SRS Endoscopic Stapling System — a type of internal stapling tool used through the throat (an endoscope) to treat gastro-oesophageal reflux disease (GORD), commonly known as acid reflux. The trial was measuring whether the procedure led to improvements in participants' reflux-related quality of life, as well as tracking serious unwanted events and changes in acid levels and medication use over six months. Of the 72 people who started, 66 co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00658775 · results posted 23 June 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,065 adults in total — 537 in one group taking esomeprazole 40mg (ESO 40mg) and 528 in another group taking rabeprazole extended-release 50mg (RAB ER 50mg). The trial was looking at people with a condition called erosive gastro-oesophageal reflux disease (eGERD) — a form of reflux where the lining of the food pipe has visible damage (erosions). The main things being measured were how many participants showed healing of those erosions (confirmed by a camera examination of the food pipe) at 4 weeks and again at 8 weeks...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00658632 · results posted 23 June 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,380 people in total — 682 were given esomeprazole (ESO) 40 mg and 698 were given rabeprazole extended release (RAB ER) 50 mg. Both are medicines commonly used for acid-related stomach conditions. The trial was measuring whether either medicine could heal damage to the lining of the food pipe (called erosive gastro-oesophageal reflux disease, or eGERD), confirmed by a camera examination of the food pipe (an endoscopy), at 4 weeks and again at 8 weeks. It also measured whether participants went at least 7 days in a ro...
-
NCT00658528 · results posted 23 June 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,055 people in total — 531 in one group who took esomeprazole 40 mg (ESO 40 mg), and 524 in another group who took a different medication, rabeprazole extended-release 50 mg (RAB ER 50 mg). The trial was looking at adults with a condition called erosive gastroesophageal reflux disease (eGERD) — a form of reflux where the lining of the food pipe shows visible damage (erosions). The main things being measured were how many participants' food pipe damage had visibly healed (confirmed by a camera examination called an en...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01990339 · results posted 11 November 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 14,965 people, all of whom received a medicine called lansoprazole. There was only one group in this study — no comparison or placebo group. Of those who started, 12,653 completed the trial, while 2,312 did not finish. The trial was measuring two main things: how much participants' stomach-related symptoms improved after four weeks of taking the medicine, and how often unwanted health events (called adverse events) were recorded during that time. The reported data shows that the primary outcome — symptom improvement...
-
NCT01642602 · results posted 6 August 2014
According to the results reported on ClinicalTrials.gov, this trial (NCT01642602) enrolled 104 adults who were given dexlansoprazole 30 mg, a medication used for heartburn. Of those, 102 people completed the four-week treatment period, and 2 did not finish. The trial was looking at two things: what unwanted health events (called adverse events — meaning any health problems that appeared or got worse after starting the medication) occurred in at least 5% of participants, and how often participants experienced days completely free of both daytime and nighttime heartburn. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01472939 · results posted 15 April 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 480 people in total across four groups. Participants were experiencing ongoing reflux symptoms (such as regurgitation and heartburn) despite already taking a common acid-reducing medicine called a proton pump inhibitor (PPI). The trial was testing whether adding different doses of an investigational medicine called SSP-002358 (at 0.1 mg, 0.5 mg, or 2.0 mg) to a PPI made any difference compared to adding a placebo (a dummy pill) to a PPI. The main thing the trial measured was the change in the percentage of days partic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00131248 · results posted 15 January 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 people in total — 9 in each of two groups. It used a "crossover" design, meaning that over the course of the study each participant took part in multiple rounds: some periods involved taking active medications and others involved taking a placebo (a dummy treatment with no active ingredient). There were three intervention periods separated by short 24-hour washout breaks (rest periods where no treatment was given). The trial was measuring episodes of bradycardia — a medical term for the heart beating more slowly th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00992589 · results posted 22 May 2013
According to the results reported on ClinicalTrials.gov, this trial involved infants being assessed for symptoms associated with gastro-oesophageal reflux (where stomach contents flow back up into the food pipe). The trial ran in two stages. In the first, open-label stage — where everyone knew what was being given — 344 infants received rabeprazole sodium 10 mg, and 267 of them went on to complete that phase. In the second, double-blind stage — where neither the families nor the researchers knew which treatment each baby was receiving — 267 of those infants were divided into three groups: 89 r...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00394472 · results posted 18 March 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 244 people in total — 122 in the AZD3355 group and 122 in the placebo (dummy treatment) group. The trial was looking at a drug called AZD3355 compared to a placebo, and was measuring symptoms of reflux — specifically "a burning feeling behind the breastbone" (heartburn) and "unpleasant movement of material upwards from the stomach" (regurgitation). Participants rated these symptoms twice a day using a diary with a six-level scale ranging from "Did not have" through to "Severe." Most participants completed the trial: 1...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 43 reported results for Gastro-oesophageal Reflux Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public research investment in Gastro-oesophageal Reflux Disease is at a moderate level, and encouragingly, that investment has been rising over time. For patients, this suggests that researchers and funding bodies see this condition as a meaningful priority, and that scientific interest in better understanding and treating it is growing. A rising funding trend often...
See the full Gastro-oesophageal Reflux Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.